CD4/CD8 Ratio Increase in Female Living with HIV Switching to Cabotegravir-Rilpivirine: A Real-Life 24 Weeks Evaluation

CD4/CD8 Ratio Increase in Female Living with HIV Switching to Cabotegravir-Rilpivirine: A Real-Life 24 Weeks Evaluation

In 2022, 20 million women globally were living with HIV, yet they remain underrepresented in clinical trials, including those for antiretroviral treatments (ART). This study assesses the safety and efficacy of the long-acting cabotegravir-rilpivirine (CAB-RPV) regimen in a cohort of 54 women living...

Full description

Saved in:
Bibliographic Details
Main Authors: Serena Spampinato, Emmanuele Venanzi Rullo, Giuseppe Nicolò Conti, Andrea De Vito, Andrea Marino, Teresa Cirelli, Viviana Coco, Alessia Mirabile, Rossella Fontana del Vecchio, Antonina Franco, Arturo Montineri, Chiara Frasca, Chiara Gullotta, Michele Salvatore Paternò Raddusa, Ylenia Russotto, Aakash Fugooah, Sarah Pulvirenti, Sonia Sofia, Grazia Pantò, Claudia Calì, Roberto Bruno, Eugenia Pistarà, Nunziatina Villari, Carmelo Iacobello, Bruno Cacopardo, Benedetto Maurizio Celesia, Giovanni F. Pellicanò, Francesco P. Antonucci, Giordano Madeddu, Sergio Lo Caputo, Giuseppe Nunnari
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Pathogens
Subjects:
HIV
long acting
Cabotegravir-Rilpivirine
CD4/CD8 ratio
Online Access:https://www.mdpi.com/2076-0817/14/7/633
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2076-0817/14/7/633

Similar Items